Search Results

A 83-01 50 mg  | 98.76%

TargetMol

A 83-01 (ALK5 Inhibitor IV) is a selective inhibitor of TGF-β type I receptor ALK5 kinase, type I activin/nodal receptor ALK4 and type I nodal receptor ALK7 with IC50 values of 12 nM, 45 nM and 7.5 nM, respectively.

More Information Supplier Page

A 83-01 10 mg  | 98.76%

TargetMol

A 83-01 (ALK5 Inhibitor IV) is a selective inhibitor of TGF-β type I receptor ALK5 kinase, type I activin/nodal receptor ALK4 and type I nodal receptor ALK7 with IC50 values of 12 nM, 45 nM and 7.5 nM, respectively.

More Information Supplier Page

Lorlatinib 5 mg  | 99.93%

TargetMol

PF-06463922 is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity.

More Information Supplier Page

Lorlatinib 50 mg  | 99.93%

TargetMol

PF-06463922 is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity.

More Information Supplier Page

Lorlatinib 25 mg  | 99.93%

TargetMol

PF-06463922 is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity.

More Information Supplier Page

Lorlatinib 10 mg  | 99.93%

TargetMol

PF-06463922 is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity.

More Information Supplier Page